Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Morgan RJ, Doroshow JH, Leong L, Schriber J, Shibata S, Forman S, Hamasaki V, Margolin K, Somlo G, Alvarnas J, McNamara M, Longmate J, Raschko J, Chow W, Vasilev S, McGonigle K, Yen Y. Morgan RJ, et al. Among authors: forman s. Bone Marrow Transplant. 2001 Nov;28(9):859-63. doi: 10.1038/sj.bmt.1703243. Bone Marrow Transplant. 2001. PMID: 11781646 Clinical Trial.
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ Jr, Doroshow JH, Venkataraman K, Chang K, Raschko J, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Margolin K, Forman S, Akman S, Coluzzi P, Ahn C, Weiss L, Gadgil U, Harrison J. Morgan RJ Jr, et al. Among authors: forman s. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2337-45. Clin Cancer Res. 1997. PMID: 9815632 Clinical Trial.
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S, Bhatia R, Chow W, Leong L, Morgan R, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Forman S, Jones D, Ashby M, Fyfe G, Hellmann S, Doroshow JH. Somlo G, et al. Among authors: forman s. Blood. 1999 May 1;93(9):2798-806. Blood. 1999. PMID: 10216073 Free article. Clinical Trial.
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies.
Somlo G, Chow W, Hamasaki V, Leong L, Margolin K, Morgan R Jr, Sniecinski I, Frankel P, Reardon D, Longmate E, Raschko J, Shibata S, O'Donnell M, Smith E, Tetef M, Forman S, Yen Y, Molina A, Doroshow H. Somlo G, et al. Among authors: forman s. Biol Blood Marrow Transplant. 2001;7(5):284-93. doi: 10.1053/bbmt.2001.v7.pm11400951. Biol Blood Marrow Transplant. 2001. PMID: 11400951 Free article. Clinical Trial.
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
VanderWalde A, Ye W, Frankel P, Asuncion D, Leong L, Luu T, Morgan R, Twardowski P, Koczywas M, Pezner R, Paz IB, Margolin K, Wong J, Doroshow JH, Forman S, Shibata S, Somlo G. VanderWalde A, et al. Among authors: forman s. Biol Blood Marrow Transplant. 2012 Aug;18(8):1273-80. doi: 10.1016/j.bbmt.2012.01.021. Epub 2012 Feb 2. Biol Blood Marrow Transplant. 2012. PMID: 22306735 Free PMC article. Clinical Trial.
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.
Somlo G, Doroshow JH, Lev-Ran A, Ahn DC, Hwang L, Raschko JW, Forman SJ, Margolin KA, Morgan RJ, Leong LA, et al. Somlo G, et al. Among authors: forman sj. J Clin Oncol. 1995 May;13(5):1231-7. doi: 10.1200/JCO.1995.13.5.1231. J Clin Oncol. 1995. PMID: 7738626 Clinical Trial.
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
Somlo G, Sniecinski I, Odom-Maryon T, Nowicki B, Chow W, Hamasaki V, Leong L, Margolin K, Morgan R Jr, Raschko J, Shibata S, Tetef M, Molina A, Berenson RJ, Forman SJ, Doroshow JH. Somlo G, et al. Among authors: forman sj. Blood. 1997 Mar 1;89(5):1521-8. Blood. 1997. PMID: 9057632 Free article.
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
Somlo G, Doroshow JH, Forman SJ, Odom-Maryon T, Lee J, Chow W, Hamasaki V, Leong L, Morgan R Jr, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Simpson J, Molina A. Somlo G, et al. Among authors: forman sj. J Clin Oncol. 1997 Aug;15(8):2882-93. doi: 10.1200/JCO.1997.15.8.2882. J Clin Oncol. 1997. PMID: 9256132
1,331 results